Sagimet Biosciences
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
155 Bovet Rd Ste 303, San Mateo, Califor...Phone Number
(650) 561-8600Website
www.sagimet.comRevenue
$5.9 MillionStock Symbol
SGMTIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Sagimet Biosciences
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of internally discovered, selective FASN inhibitors for the treatment of several therapeutic areas of high unmet medical need including liver disease and specific cancers targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASN inhibitors.Explore more
Sagimet Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sagimet Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Sagimet Biosciences had a recent Job posting/layoffs
Check if Sagimet Biosciences has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Sagimet Biosciences has new funding data
Congratulate Masked Content for being promoted to Masked Content at Sagimet Biosciences
Check out if Sagimet Biosciences is spiking on competitors!
Product Launch: Get notified when Sagimet Biosciences launches new products
Earning: See what the market has to say on Sagimet Biosciences recently announced quarterly report
Website visits: Recent activity has been detected on your website
Sagimet Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Sagimet Biosciences
Find 2 more new buyers
Compare Similar Companies to Sagimet Biosciences
Compare insights from companies similar to Sagimet Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sagimet Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sagimet Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sagimet Biosciences.
Sagimet Biosciences financials insights
Gather financial insights about Sagimet Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Series A
$7.6M
2009
Series B
$30M
2013
Series C
$20M
2014
Series D
$28.5M
2019
Series E
$25M
2021
Other Financing Round
$80M
Sagimet Biosciences Tech Stack
A closer look at the technologies used by Sagimet Biosciences
See more technologies
Most Recent Scoops
Project
Sagimet Biosciences is developing a topical FASN inhibitor targeting mild acne patients, currently in formulation development, with first-in-human studies planned for early 2028.
Product Development, Pharmaceuticals
Project
reported that the 52-week open-label extension data from the Ascletis trial of denifanstat demonstrated sustained safety and tolerability alongside continued improvements in IGA scores and lesion count reductions beyond the initial 12-week period, with 52-week lesion count reductions approaching those observed with Accutane.
Clinical Operations
Project
Sagimet Biosciences is advancing its second oral FASN inhibitor, a more potent version of denifanstat, with Phase II initiation expected by year-end following the completion of Phase I, and Phase II data anticipated by the end of next year. The Phase II objective is to determine whether increased potency translates to greater treatment response without compromising the established safety and tolerability profile.
Research & Development, Pharmaceuticals
Project
reported that the Ascletis Phase III trial of denifanstat demonstrated a favorable safety profile, with no Grade 3 or serious adverse events observed, and only mild to moderate occurrences of dry eye (slightly above 10% active vs. approximately 9% placebo) and dry skin (approximately 6% active vs. 2% placebo).
Clinical Operations
Open Position
Sagimet Biosciences News & Media
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced positive 52-week results from the Phase 3 ASC40-304 OLE clinical trial of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner Ascletis BioScience Co. Ltd. (Ascletis) in China. The results were presented at the EuropeaSagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
FOSTER CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, September 30, 2026, at 1:00 PM ET featuring Julie Harper, MD, Founding Director and past President of the American Acne and Rosacea Society. To register, click here.Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
All clinical trial sites identified and CRO retained
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sagimet Biosciences
Sign Up For FreeTo access detailed company insights
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of internally discovered, selective FASN inhibitors for the treatment of several therapeutic areas of high unmet medical need including liver disease and specific cancers targeting dysfunctional metabolic pathways. The company has unique expertis... Read More
